Sumitomo Pharma Stock Drops Sharply After Regulatory Milestone for Pioneering Cell Therapy

In a surprising market reversal, shares of Sumitomo Pharma tumbled more than 12% on Friday. The drop came just one day after Japanese regulators endorsed the company's innovative therapy for Parkinson's disease, a treatment developed from induced pluripotent stem (iPS) cells. The decline is widely viewed as a wave of profit-taking following an extraordinary rally; the stock had surged over 300% last year and recently reached its highest price since 2019.

The government's decision marks a significant achievement for Japan's domestic push into advanced cellular medicine. Formal approval from the Ministry of Health, Labor and Welfare is expected within two months. The therapy is rooted in the foundational work of Nobel laureate Shinya Yamanaka, who first created iPS cells in 2006.

Despite the long-term potential for the treatment in Japan and the United States, analysts tempered immediate expectations. "We foresee almost no profit contribution in the near term," noted Citigroup analyst Hidemaru Yamaguchi, describing the stock's recent climb as excessive. Sumitomo Pharma, which markets drugs for neuroscience, oncology, and regenerative medicine, now faces the challenge of translating scientific validation into commercial success while managing investor expectations.

Source: CNBC